Vaccine Therapy in Treating Patients With Liver Cancer

NCT ID: NCT00005629

Last Updated: 2020-08-03

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1/PHASE2
• Total Enrollment: 6 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 1999-07-31
• Study Completion Date: 2002-06-30

Brief Summary

RATIONALE: Vaccines may make the body build an immune response to kill tumor cells.

PURPOSE: Phase I/II trial to study the effectiveness of vaccine therapy in treating patients who have liver cancer.

Conditions

Liver Cancer

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Group A - first dosing group

Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides (100 ug dose) emulsified in 2 ml of Montanide ISA-51.

Group Type: EXPERIMENTAL

AFP gene hepatocellular carcinoma vaccine

Intervention Type: BIOLOGICAL

Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.

Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug

Arm B - dosing group 2

Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides (500 ug dose) emulsified in 2 ml of Montanide ISA-51.

Group Type: EXPERIMENTAL

AFP gene hepatocellular carcinoma vaccine

Intervention Type: BIOLOGICAL

Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.

Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug

Group 3 - dosing level 3

Patients will receive three biweekly intradermal vaccinations with four HLA-A\*0201-binding AFP-derived peptides (1000 ug dose) emulsified in 2 ml of Montanide ISA-51.

Group Type: EXPERIMENTAL

AFP gene hepatocellular carcinoma vaccine

Intervention Type: BIOLOGICAL

Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.

Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug

Interventions

AFP gene hepatocellular carcinoma vaccine

Patients will receive three biweekly intradermal vaccinations with four HLA-A*0201-binding AFP-derived peptides emulsified in 2 ml of Montanide ISA-51.

Group A AFP peptide dose 100 ug Group B AFP peptide dose 500 ug Group C AFP peptide dose 1000 ug

Intervention Type: BIOLOGICAL

Eligibility Criteria

Inclusion Criteria

• This study will enroll HLA-A 0201 adults over the age of 18 with history of biopsy-proven HCC and AFP positive by immunohistochemistry or serum AFP levels > 2 times above the upper limit of normality. Any stage of disease will be eligible.
• Both male and female patients may be enrolled. Females of childbearing potential must have a negative pregnancy test prior to treatment.
• Patients must be ambulatory with a Karnofsky Performance Status greater than or equal to 70 percent.
• No previous evidence of class 3 or greater New York Heart Association cardiac insufficiency or coronary artery disease.
• No evidence of opportunistic infection.
• A minimum of 4 weeks must have elapsed since the completion of prior chemotherapy or radiation therapy.
• Adequate baseline hematological function as assessed by the following laboratory values within 30 days prior to study entry (day -30 to 0):

• Hemoglobin > 8.5 g/dl (patients cannot be transfusion dependent).
• Platelets > 30,000/mm3
• WBC > 2,000/mm3
• Absolute Neutrophil Count (ANC) > 1,000/mm3
• Positive skin test to common antigens (tetanus and/or candida).
• Ability to give informed consent and signed informed consent.

Exclusion Criteria

Patients who meet any one of the following criteria will be excluded from study entry:

• Any congenital or acquired condition leading to inability to generate an immune response, including concomitant immune suppressive therapy. The ability to adequately respond to antigens will be tested before trial entry by requiring a positive response to skin allergens (tetanus and candida).
• Lactating females: All patients must practice adequate birth control and females of child-bearing potential must have a negative serum HCG pregnancy test (within day -7 to day 0).
• Acute infection: any acute viral, bacterial, or fungal infection, which requires specific therapy. Acute therapy must have been completed within 14 days prior to study treatment.
• HIV-infected patients, due to concerns in the ability to stimulate an effective immune response.
• Acute medical problems such as ischemic heart or lung disease that may be considered an unacceptable anesthetic or operative risk.
• Patients with any underlying conditions that would contraindicate therapy with study treatment (or allergies to reagents used in this study).
• Patients with organ allografts.
• Uncontrolled hepatic insufficiency and cirrhosis, Class C in the Child's classification, with bilirubin > 3 mg/dl, albumin < 3.0 g/dl, poorly controlled ascites, advanced encephalopathy and poor nutritional status.
• Uncontrolled CNS metastasis. Patients with previously known CNS metastasis will be eligible if they have received CNS irradiation to control local tumor growth.
• Concomitant Medication and Treatment:

All allowed medications or treatments should be kept to a minimum and recorded.

• Concomitant Medications and Treatments Not Allowed: Corticosteroids, Cyclosporin A, cytotoxic chemotherapy.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

National Institutes of Health (NIH)

NIH

Sponsor Role: collaborator

Jonsson Comprehensive Cancer Center

OTHER

Sponsor Role: lead

Responsible Party

UCLA

Principal Investigators

James S. Economou, MD

Role: STUDY_CHAIR

Jonsson Comprehensive Cancer Center

Locations

Jonsson Comprehensive Cancer Center, UCLA

Los Angeles, California, United States

Countries

United States

Other Identifiers

UCLA-9905003

Identifier Type: -

Identifier Source: secondary_id

NCI-H00-0053

Identifier Type: -

Identifier Source: secondary_id

CDR0000067782

Identifier Type: -

Identifier Source: org_study_id